Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.
2.

Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.

Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosoya T.

Hypertens Res. 2002 Nov;25(6):849-55.

3.

Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.

Fujisawa T, Ikegami H, Ono M, Nishino M, Noso S, Kawabata Y, Ogihara T.

Am J Hypertens. 2005 Jan;18(1):13-7.

PMID:
15691611
4.

Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.

Mazerska M, Myƛliwiec M.

Adv Med Sci. 2009;54(1):37-40. doi: 10.2478/v10039-009-0015-6.

PMID:
19505872
5.

Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.

Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ.

Nephrol Dial Transplant. 2006 Mar;21(3):683-9. Epub 2005 Dec 5.

PMID:
16330466
6.

Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.

Krimholtz MJ, Karalliedde J, Thomas S, Bilous R, Viberti G.

J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S42-7.

7.

Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).

Imai E, Haneda M, Yamasaki T, Kobayashi F, Harada A, Ito S, Chan JC, Makino H.

Hypertens Res. 2013 Dec;36(12):1051-9. doi: 10.1038/hr.2013.86. Epub 2013 Sep 12.

9.

Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.

Krairittichai U, Chaisuvannarat V.

J Med Assoc Thai. 2009 May;92(5):611-7.

PMID:
19459520
10.

Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.

Abe H, Minatoguchi S, Ohashi H, Murata I, Minagawa T, Okuma T, Yokoyama H, Takatsu H, Takaya T, Nagano T, Osumi Y, Kakami M, Tsukamoto T, Tanaka T, Hiei K, Fujiwara H.

Hypertens Res. 2007 Oct;30(10):929-35.

PMID:
18049024
11.

Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.

Knudsen ST, Andersen NH, Poulsen SH, Eiskjaer H, Hansen KW, Helleberg K, Poulsen PL, Mogensen CE.

Am J Hypertens. 2008 Feb;21(2):172-6. doi: 10.1038/ajh.2007.2. Epub 2008 Jan 10.

PMID:
18188164
12.

Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.

Katayama S, Yagi S, Yamamoto H, Yamaguchi M, Izumida T, Noguchi Y, Inaba M, Inukai K.

Hypertens Res. 2007 Jun;30(6):529-33.

PMID:
17664856
13.

Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.

Homma K, Hayashi K, Kanda T, Yoshioka K, Takamatsu I, Tatematsu S, Kumagai H, Wakino S, Saruta T.

J Hum Hypertens. 2004 Dec;18(12):879-84.

PMID:
15295613
14.

Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.

Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K.

Am J Hypertens. 2007 Nov;20(11):1195-201.

PMID:
17954367
16.

Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.

Okura T, Kojima M, Machida H, Sugiyama M, Kato T, Komada T, Miyazaki T, Ninomiya T, Ichikawa T, Nakatani K, Watanabe Y, Dohi Y, Ito M, Kimura G.

J Hum Hypertens. 2012 Apr;26(4):214-9. doi: 10.1038/jhh.2011.22. Epub 2011 Mar 17.

PMID:
21412266
18.

Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria.

Saito F, Fujita H, Takahashi A, Ichiyama I, Harasawa S, Oiwa K, Takahashi N, Otsuka Y, Uchiyama T, Kanmatsuse K, Kushiro T.

Hypertens Res. 2007 Jan;30(1):39-47.

PMID:
17460370
19.

Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).

Maeda A, Tamura K, Kanaoka T, Ohsawa M, Haku S, Azushima K, Dejima T, Wakui H, Yanagi M, Okano Y, Fujikawa T, Toya Y, Mizushima S, Tochikubo O, Umemura S.

Clin Exp Hypertens. 2012;34(4):249-57. doi: 10.3109/10641963.2012.681081. Epub 2012 May 9.

PMID:
22571446
20.

Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.

Fogari R, Corradi L, Zoppi A, Lazzari P, Mugellini A, Preti P, Rinaldi A.

Am J Hypertens. 2007 Oct;20(10):1092-6.

PMID:
17903693

Supplemental Content

Support Center